查詢結果分析
來源資料
相關文獻
- Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor for Survival in Patients with Advanced Non-small Cell Lung Cancer
- 非小細胞肺癌術前輔助性化學治療的經驗
- The Role of Radiotherapy for Advanced Non-Small Cell Lung Cancer
- Differential Display of mRNA in Human Lung Tissue and in Non-Small Cell Lung Cancer: A Preliminary Report
- 非小細胞肺癌的治療
- 晚期非小細胞肺癌之化學治療
- CA405之基因療法合併化學抗癌藥物對肺癌細胞之作用效果評估與機轉的探討(2)
- Treatment of Non-Small-Cell Lung Cancer: The Chinese Experience in a General Teaching Hospital
- erbB基因與非小細胞肺癌的原發抗藥性
- Concurrent 5-Fluorouracil, Leucovorin, Etoposide, Cisplatin and Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
頁籤選單縮合
題 名 | Pretreatment Neutrophil/Lymphocyte Ratio as a Prognostic Factor for Survival in Patients with Advanced Non-small Cell Lung Cancer=治療前嗜中性白血球/淋巴球比值可作為非小細胞肺癌患者存活之預測因子 |
---|---|
作 者 | 葉金水; 紀炳銓; 陳正雄; 蔡偉宏; 林慶雄; | 書刊名 | 胸腔醫學 |
卷 期 | 28:6 2013.12[民102.12] |
頁 次 | 頁321-329 |
分類號 | 415.468 |
關鍵詞 | 嗜中性白血球/淋巴球比例值; 存活預測因子; 非小細胞肺癌; Neutrophil/lymphocyte ratio; Prognostic factor; Non-small cell lung cancer; |
語 文 | 英文(English) |
中文摘要 | 背景:週邊嗜中性白血球,淋巴球數目及嗜中性白血球/淋巴球比值(NLR)據研究顯示與非小細胞肺癌患者存活有關。本研究探討NLR作為非小細胞肺癌第IIIB及第IV期患者存活之預測因子。方法:非小細胞肺癌第IIIB及第IV期患者於2004年1月至2006年12月曾接受放射線治療或化學治療納入此回溯性研究。紀錄分析患者接受治療前週邊血液常規檢查及白血球分類比。臨床病理因子及NLR以單變數分析和多變數分析。總存活曲線以Kaplan-Meier法行存活分析,高NLR比值與低NLR比值組的存活差異以log-rank法檢定。結果:375個非小細胞肺癌患者包含246位男性及129位女性平均66.7歲納入研究。低NLR值與高NLR值組的存活中數分別為10.15及2.20個月(p<0.001)。治療前NLR值為存活獨立癒後因子。多變數分析顯示年紀小於66歲及體能狀態亦為獨立癒後因子。晚期非小細胞肺癌患者NLR值升高可能存活較差。結論:NLR值為一容易測量並且可能作為晚期非小細胞肺癌患者存活之預測因子。 |
英文摘要 | Introduction: Peripheral neutrophils, lymphocyte counts and the neutrophil/lymphocyte ratio (NLR) have been associated with survival of patients with non-small cell lung cancer (NSCLC). In this study, we investigated the prognostic effect of NLR on overall survival of stage IIIB and IV NSCLC patients.Methods: Patients with stage IIIB and IV NSCLC who underwent radiotherapy or chemotherapy between January 2004 and December 2006 were studied retrospectively. The complete blood count data with differential counts of peripheral blood before chemotherapy or radiotherapy were analyzed. The prognostic effect of clinicopathological factors and NLR were examined by univariate and multivariate analysis. Overall survival curves were derived using the Kaplan-Meier method, and the difference between the high and low NLR groups was assessed by log-rank test.Results: In all, 375 eligible NSCLC patients, including 246 men and 129 women with a mean age of 66.7 years, were enrolled. Median overall survival durations of the low NLR (NLR<8.91) and high NLR groups (NLR≥8.91) were 10.15 and 2.20 months, respectively (p<0.001). The pretreatment NLR was an independent prognostic factor for overall survival (hazard ratio: 1.966; 95% CI: 1.527-2.532; p<0.001), Multivariate analysis showed that age younger 66 years and performance status were independent prognostic factors. Increased pretreatment NLR was associated with a poor prognosis for advanced NSCLC patients.Conclusions: NLR is easily measured and may be utilized as a reliable prognostic predictor for advanced NSCLC. |
本系統中英文摘要資訊取自各篇刊載內容。